SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT00752076

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Detection of Epithelial Growth Factor Receptor (EGFR) Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment

1. Detection EGFR mutation of cancer cells from malignant pleural effusion. 2. Established the cancer cell lines with without EGFR mutation from malignant pleural effusion.

NCT00752076 NSCLC
MeSH: Pleural Effusion Pleural Effusion, Malignant
HPO: Pleural effusion

1 Interventions

Name: cancer cell lines establishment

Description: Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment

Type: Other

1


Primary Outcomes

Measure: EGFR mutation in malignant pleural effusion of lung cancer patients cancer cell lines establishment

Time: 1 year

Purpose: Basic Science

Single Group Assignment


There is one SNP

SNPs


1 L858R

In-frame deletions in exon 19 centered on codons 756 to 750 make up 45~50% of mutations, and another 35~45% consist of the missense mutation leucine to arginine at codon 858 (L858R) in exon 21 (8, 9, 10). --- L858R ---

It is interesting that exon 19 deletion have increased response and survival with TKIs compared with L858R cases (10, 13, 14). --- L858R ---

This is in contrast to the natural history of patients, where those with exon 19 deletions appear to have shorter survival than those with L858R (8). --- L858R ---



HPO Nodes


HPO:
Pleural effusion
Genes 50
RIT1 IL10 CFH HFE MST1 MYD88 IL12A PRSS1 TCF4 FAT4 PLVAP TAPT1 HLA-B SPINK1 ADAMTS3 IGH ERAP1 INHBA LACC1 GPR35 IL12A-AS1 CCBE1 HLA-DRB1 PIEZO1 BTNL2 MIF TLR4 FSHR SOX18 CCR1 UBAC2 C4A TSC1 TSC2 CCND1 CD46 BCL2 LBR BCL6 CFI FAS CBL KLRC4 DNASE1L3 IL6 MEFV IL23R STAT4 KIF11 HELLPAR